RU2020130048A - Модуляторы sting (стимулятора генов интерферона) на основе циклопентана - Google Patents

Модуляторы sting (стимулятора генов интерферона) на основе циклопентана Download PDF

Info

Publication number
RU2020130048A
RU2020130048A RU2020130048A RU2020130048A RU2020130048A RU 2020130048 A RU2020130048 A RU 2020130048A RU 2020130048 A RU2020130048 A RU 2020130048A RU 2020130048 A RU2020130048 A RU 2020130048A RU 2020130048 A RU2020130048 A RU 2020130048A
Authority
RU
Russia
Prior art keywords
compound
salt according
salt
pharmaceutically acceptable
hydrogen
Prior art date
Application number
RU2020130048A
Other languages
English (en)
Russian (ru)
Other versions
RU2020130048A3 (enExample
Inventor
Мартин Джеймс Уайтс
Индраван Джеймс Макалпайн
Райан ПЭТМАН
Юджин Яньцзинь ЖУЙ
Эндрю Фенсом
Андреас Мадерна
Мехран ДЖАЛЭЙ
Кетан С. Гадживала
Original Assignee
Пфайзер Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Инк. filed Critical Пфайзер Инк.
Publication of RU2020130048A3 publication Critical patent/RU2020130048A3/ru
Publication of RU2020130048A publication Critical patent/RU2020130048A/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/6574Esters of oxyacids of phosphorus
    • C07F9/65744Esters of oxyacids of phosphorus condensed with carbocyclic or heterocyclic rings or ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • C07H19/20Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/213Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
RU2020130048A 2018-03-15 2019-03-12 Модуляторы sting (стимулятора генов интерферона) на основе циклопентана RU2020130048A (ru)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862643467P 2018-03-15 2018-03-15
US62/643,467 2018-03-15
US201862666204P 2018-05-03 2018-05-03
US62/666,204 2018-05-03
US201862742532P 2018-10-08 2018-10-08
US62/742,532 2018-10-08
US201962809990P 2019-02-25 2019-02-25
US62/809,990 2019-02-25
PCT/IB2019/052009 WO2019175776A1 (en) 2018-03-15 2019-03-12 Cyclopentane-based modulators of sting (stimulator of interferon genes)

Publications (2)

Publication Number Publication Date
RU2020130048A3 RU2020130048A3 (enExample) 2022-04-15
RU2020130048A true RU2020130048A (ru) 2022-04-15

Family

ID=66103038

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2020130048A RU2020130048A (ru) 2018-03-15 2019-03-12 Модуляторы sting (стимулятора генов интерферона) на основе циклопентана

Country Status (25)

Country Link
US (4) US10538542B2 (enExample)
EP (1) EP3765474B1 (enExample)
JP (1) JP7266942B2 (enExample)
KR (1) KR20200131878A (enExample)
CN (1) CN111918871A (enExample)
AU (1) AU2019234043A1 (enExample)
BR (1) BR112020018593A2 (enExample)
CA (1) CA3093631C (enExample)
CL (1) CL2020002352A1 (enExample)
CR (1) CR20200382A (enExample)
DO (1) DOP2020000160A (enExample)
EC (1) ECSP20057847A (enExample)
ES (1) ES2923298T3 (enExample)
IL (1) IL277278A (enExample)
MA (1) MA52012A (enExample)
MX (1) MX2020009587A (enExample)
NI (1) NI202000058A (enExample)
PE (1) PE20210412A1 (enExample)
PH (1) PH12020551486A1 (enExample)
PY (1) PY1919127A (enExample)
RU (1) RU2020130048A (enExample)
SG (1) SG11202008102VA (enExample)
TW (1) TWI741268B (enExample)
UY (1) UY38145A (enExample)
WO (1) WO2019175776A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3728283B1 (en) 2017-12-20 2023-11-22 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
WO2019123339A1 (en) 2017-12-20 2019-06-27 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
US10538542B2 (en) * 2018-03-15 2020-01-21 Pfizer Inc. Cyclopentane-based modulators of STING (stimulator of interferon genes)
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TW202028179A (zh) 2018-10-08 2020-08-01 美商普萊恩醫療公司 胺基酸化合物及使用方法
KR20220070254A (ko) 2019-09-25 2022-05-30 화이자 인코포레이티드 Sting (인터페론 유전자의 자극인자)의 폴리헤테로시클릭 조정제
TW202200136A (zh) 2020-04-10 2022-01-01 日商小野藥品工業股份有限公司 癌治療方法
WO2022122613A1 (en) * 2020-12-08 2022-06-16 F. Hoffmann-La Roche Ag Novel synthesis of phosphorodithioate oligonucleotides
US11964978B2 (en) * 2021-03-18 2024-04-23 Pfizer Inc. Modulators of STING (stimulator of interferon genes)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
CR20160564A (es) * 2014-06-04 2017-01-20 Glaxosmithkline Ip Dev Ltd Dinucleótidos cíclicos como moduladores de sting
GB201501462D0 (en) 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
US10538542B2 (en) * 2018-03-15 2020-01-21 Pfizer Inc. Cyclopentane-based modulators of STING (stimulator of interferon genes)

Also Published As

Publication number Publication date
KR20200131878A (ko) 2020-11-24
UY38145A (es) 2019-10-31
RU2020130048A3 (enExample) 2022-04-15
MA52012A (fr) 2021-01-20
CN111918871A (zh) 2020-11-10
IL277278A (en) 2020-10-29
EP3765474A1 (en) 2021-01-20
TWI741268B (zh) 2021-10-01
PE20210412A1 (es) 2021-03-04
PY1919127A (es) 2020-08-26
MX2020009587A (es) 2020-10-05
DOP2020000160A (es) 2020-09-30
CA3093631A1 (en) 2019-09-19
US20230382932A1 (en) 2023-11-30
JP7266942B2 (ja) 2023-05-01
CL2020002352A1 (es) 2020-12-18
US10538542B2 (en) 2020-01-21
CA3093631C (en) 2023-01-24
SG11202008102VA (en) 2020-09-29
NI202000058A (es) 2021-01-08
TW201945036A (zh) 2019-12-01
EP3765474B1 (en) 2022-06-15
JP2021518335A (ja) 2021-08-02
CR20200382A (es) 2020-12-10
US20210230196A1 (en) 2021-07-29
AU2019234043A1 (en) 2020-09-17
ECSP20057847A (es) 2021-04-29
WO2019175776A1 (en) 2019-09-19
US10968242B2 (en) 2021-04-06
US20190284216A1 (en) 2019-09-19
ES2923298T3 (es) 2022-09-26
BR112020018593A2 (pt) 2020-12-29
PH12020551486A1 (en) 2021-08-23
US20200102334A1 (en) 2020-04-02

Similar Documents

Publication Publication Date Title
RU2020130048A (ru) Модуляторы sting (стимулятора генов интерферона) на основе циклопентана
TWI713889B (zh) 胜肽化合物之環化方法
JP2021112211A5 (enExample)
Manoel-Caetano et al. Implications of genetic variability of Trypanosoma cruzi for the pathogenesis of Chagas disease
WO2003064621A3 (en) HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES
ECSP22022958A (es) Moduladores poliheterociclicos de sting (estimulador de genes de interferón)
JP2018076342A (ja) フラビウィルス科ウィルス感染治療用の修飾2’および3’−ヌクレオシドプロドラッグ
CN107148424A (zh) 用于诱导细胞因子的环状二核苷酸
KR20050035194A (ko) 플라비비리다에 감염 치료용 2'-c-메틸-3'-o-l-발린에스테르 리보푸라노실 사이티딘
PE40996A1 (es) Derivado de antibiotico de glucopeptido
DK379089A (da) Tetrahydro-1-benzoec,daaindolpropionsyre-sulfonamider, deres fremstilling og anvendelse
JP2017522273A (ja) Hiv治療におけるアポトーシスタンパク質阻害剤(iap)のアンタゴニストの使用
RU2003103101A (ru) Плеуромутилиновые производные, обладающие антибактериальной активностью
EA202092069A1 (ru) Композиции и способы лечения макулярной дистрофии
DE60325377D1 (de) Motilidverbindungen
Sumpf et al. Histone deacetylase inhibitor MS-275 augments expression of a subset of IFN-γ-regulated genes in Toxoplasma gondii-infected macrophages but does not improve parasite control
ES468918A1 (es) Procedimiento para la preparacion de complejos de peptido
MX2023013017A (es) Anticuerpos anti citolítico natural grupo 2, miembro d (nkg2d) y usos de estos.
Kaminer Search and Discovery: A Tribute to Albert Szent-Györgyi
JPS6419005A (en) Agent for promoting growth of mycelia and formation of fruit body of basidiomycetes
RU2004119841A (ru) Гексациклические соединения
Stephens Turnover of tubulin in ciliary outer doublet microtubules
Kulaeva et al. Molecular mechanisms of transcription through a nucleosome by RNA polymerase II
SU531885A1 (ru) Сплав на основе магни
Kim et al. Cefoperazone (Cefobid) for treating men with gonorrhoea caused by penicillinase producing Neisseria gonorrhoeae.